News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice Of Allowance From U.S. Patent Office For Treatment And Prevention Of Neuro And Muscular Degenerative Diseases


1/16/2014 8:49:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or “RegeneRx”) today announced that it has received a Notice of Allowance of a U.S. patent application for using Thymosin beta 4 (Tß4) and various fragments and other related peptides for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage. The patent will expire in 2026.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES